A COMPARATIVE STUDY OF TENIDAP, A CYTOKINE-MODULATING ANTI-RHEUMATIC DRUG, AND DICLOFENAC IN RHEUMATOID ARTHRITIS: A 24-WEEK ANALYSIS OF A 1-YEAR CLINICAL TRIAL

Tenidap is a novel anti-rheumatic drug that combines cytokinemodulation with cyclo-oxygenase inhibition. This 24-week, multicentre,double-blind, randomized study compared the clinical efficacy,biochemical effects and safety of tenidap 120 mg/day (once daily)with diclofenac 150 mg/day (50 mg t.i.d.) in the treatment of384 patients with active rheumatoid arthritis. After 24 weeks,improvement with tenidap was significantly greater than withdiclofenac for all five primary efficacy parameters, two ofthe four secondary efficacy parameters and 11 of the 13 ArthritisImpact Measurement Scales assessments. The superior efficacyof tenidap was apparent after 4 weeks of treatment with furtherimprovements observed by 24 weeks. The probability of discontinuationdue to lack of efficacy was significantly greater in the diclofenacgroup. Tenidap but not diclofenac was associated with significant,rapid and sustained reductions in C-reactive protein and serumamyloid A levels and with a significant reduction in plasmainterleukin-6. The nature and frequency of side-effects weresimilar in the two groups as was the discontinuation rate fortreatment-related safety reasons. Tenidap was associated withan equal incidence of elevated transaminases, but a higher incidenceof mild (     

Haemoptysis in healthy children due to unsuspected foreign body

Abstract: Haemoptysis in otherwise healthy children is an uncommon event. Two cases of massive haemoptysis, subsequently requiring lobectomy, are discussed. In each case, foreign vegetable matter was identified despite previously normal bronchoscopy and minimal changes on chest radiograph.     

Actuarial survival in the premature infant less than 30 weeks' gestation

OBJECTIVE: Because survival from admission to discharge does not provide parents and physicians information about future life expectancy in the premature neonate, we characterized the actuarial survival, defined as the future life expectancy from a given postnatal age, in a large inborn population of premature infants < 30 weeks' gestation. STUDY DESIGN: We determined daily actuarial survival of 1925 inborn infants (23 to 29 weeks' gestation) admitted to the Baylor Affiliated Nurseries from July 1986 through December 1994, stratified by 100-g birth weight and by 1-week gestational-age intervals. RESULTS: In the 501- to 600-g birth weight stratum, actuarial survival improved from 31% at birth, to 61% on day of life 7, and then to 75% on day of life 28; in the 901- to 1000-g birth weight stratum, actuarial survival improved from 88%, to 94%, and then to 98% throughout the same times, respectively. Similar trends were obtained when data were stratified by gestational age. CONCLUSIONS: Survival in the smallest infants improves dramatically during the first few days of life, but there is a significant risk for late death in the smallest of these infants.     

外源核苷酸对免疫抑制小鼠胸腺细胞DNA损伤的影响

目的:检测外源核苷酸对经环磷酰胺诱导的免疫抑制小鼠胸腺细胞DNA损伤的影响。方法:采用18～20 g昆明种小鼠30只,雌雄各半,随机分成阴性对照组(NEC)、阳性对照组(POC)和核苷酸组(NTG),每组10只。NEC组和POC组小鼠均饲喂半纯合无核苷酸的基础日粮,NTG组则在基础日粮中添加0.25%的核苷酸,实验期为21 d。在实验结束前18 h POC组和NTG组小鼠按照150mg/kg bw的剂量腹腔注射环磷酰胺,NEC组注射生理盐水,实验结束时测定脾脏和胸腺脏器指数,并取胸腺细胞,做单细胞凝胶电泳,观察细胞DNA损伤情况。结果:在基础日粮中添加核苷酸对小鼠免疫器官重量没有显著影响(P>0.05),但能极显著降低受损胸腺细胞百分率(P<0.01)和受损细胞DNA尾长(P<0.01)。结论:外源核苷酸能显著降低免疫抑制小鼠受损胸腺细胞百分率和损伤程度。     

胃泌素受体在胃癌组织中表达的特征及其预后价值

目的探讨胃泌素受体（ｇａｓｔｒｉｎｒｅｃｅｐｔｏｒ,ＧＲ）在胃癌自分泌生长中的作用及其与胃癌预后的关系。方法应用胃泌素受体的放射配基结合分析法,测定３４例胃癌组织胃泌素受体的含量及其亲和力。结果３４例胃癌中,胃癌组织胃泌素受体阳性１６例,其中低亲和力胃泌素受体２例;高亲和力胃泌素受体１４例,高含量胃泌素受体９例,低含量胃泌素受体５例。２４例Ⅲ、Ⅳ期胃癌中,胃癌组织胃泌素受体阳性１５例;１０例Ⅰ、Ⅱ期胃癌中,胃癌组织胃泌素受体阳性仅１例。胃癌组织胃泌素受体的表达与胃癌临床病理分型无关。胃泌素受体阳性的胃癌细胞Ｓ期细胞比例及超５倍体细胞比例均高于胃泌素受体阴性者。对３１例胃癌患者随访３１～６９个月,胃泌素受体阴性或低亲和力胃泌素受体的胃癌患者,其预后较高亲和力胃泌素受体者好。结论胃泌素受体易于在晚期胃癌中表达,其对评估胃癌患者的预后有一定参考价值。